Synergy Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Synergy Pharmaceuticals Inc.
SPDR S&P Biotech ETF
8,867,439
3.58%
22,812
0.3%
09/06/2018
Vanguard Small Cap Index Fund
5,928,301
2.39%
93,522
0.01%
07/31/2018
Vanguard Total Stock Market Index Fund
5,879,357
2.37%
0
0%
07/31/2018
iShares Russell 2000 ETF
4,939,299
1.99%
-2,637
0.02%
09/06/2018
Vanguard Small Cap Value Index Fund
3,703,241
1.49%
14,201
0.02%
07/31/2018
Vanguard Extended Market Index Fund
3,258,895
1.31%
-1,571
0.01%
07/31/2018
iShares Nasdaq Biotechnology ETF
2,845,281
1.14%
-37,212
0.06%
09/06/2018
iShares Russell 2000 Growth ETF
2,398,038
0.97%
0
0.04%
09/06/2018
iShares US Pharmaceuticals ETF
2,030,522
0.82%
0
0.84%
09/06/2018
Fidelity Spartan Extended Market Index Fund
1,167,811
0.47%
0
0.01%
07/31/2018
| Address |
420 Lexington Avenue
New York New York 10170
United States
|
|
Employees
|
- |
| Website |
http://www.synergypharma.com |
| Updated |
09/14/2018 |
| Synergy Pharmaceuticals, Inc. engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai on November 15, 2005 and is headquartered in New York, NY. |
